Discussion: As adjuvant systemic treatments become more effective, guidelines become less restrictive, resulting in more patients being selected for adjuvant therapy. Since newer treatment guidelines do not better predict survival, the magnitude of the 70-gene profiles benefit, which is defined as proportion of patients in whom over-and undertreatment can be avoided, depends on present guidelines for risk assessment and shows a remarkable increase.
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